The global high resolution melting analysis market size is expected to reach USD 385.6 billion by 2030, growing at a CAGR of 3.32% from 2023 to 2030, according to a new report by Grand View Research Inc. Increasing incidences of cancer, sickle cell anemia, HIV and other STDs are expected to positively reinforce demand for smart and simple molecular diagnostics.
Based on analyzing the disease trends and relatively lower treatment rates suggests that the demand for gene mutation and other genomic tests are expected to increase significantly over the next few years. Recent developments in the field of QPCR, next generation sequencing, genomics and big data analytics have been instrumental in strengthening the precision medicine approach. The U.S. FDA has already approved some of the treatments which are designed to meet the requirements of a specific genetic makeup or the genomic profile of the patient’s tumor.
For instance, the U.S FDA has approved a new treatment for cystic fibrosis (CF) in January, 2012. The drug kalydeco was approved for patients reported to have a specific genetic mutation known as “G551D mutation. The number of mutations which can lead to CF is in hundreds, and the G551D mutation is responsible for nearly 4% of the cases in the U.S.
Furthermore, in 2015, the Obama administration has announced the Precision Medicine Initiative with an investment of USD 216 million in the 2016 president's budget. This initiative is expected to positively reinforce the HRM analysis market over the forecast period.
Request a free sample copy or view report summary: High Resolution Melting Analysis Market Report
Clinical diagnostics is anticipated to be the fastest-growing segment, with a CAGR of 4.6% through 2030
The detection of acquired mutations/mutation scanning/SNP typing segment held a significant revenue share in 2022 and the segment is also expected to advance at a significant CAGR over the forecast period.
In 2022, North America dominated the overall HRM analysis market with a share of nearly 45%. Key factors attributed are high disease prevalence rates, presence of large number of academic universities; strong pharmaceutical and biotech industry, presence of large number genetic testing centers, and rapid adoption of novel technologies for improving the healthcare outcomes.
Asia pacific is identified as the fastest growing region over the forecast period. Key reasons attributed are increasing public and private expenditure on molecular diagnostics and genetic testing, increasing prevalence of genetic disorders, and increasing burden of chronic diseases such as cancer, COPD, HIV and others.
Grand View Research has segmented the global high resolution melting analysis market report on the basis of product, application, end-use, and region
High Resolution Melting Analysis Product Outlook (Revenue, USD Million, 2018 - 2030)
Reagents
Instruments
Software
High Resolution Melting Analysis Application Outlook (Revenue, USD Million, 2018 - 2030)
Detection of Acquired Mutations/Mutation Scanning/SNP Typing
Microbial Species Identification
Zygosity Testing
Epigenetics/Methylation Profiling and Drug-Resistant
High Resolution Melting Analysis End-use Outlook (Revenue, USD Million, 2018 - 2030)
Academic Research
Clinical Diagnostics
High Resolution Melting Analysis Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
List of Key Players of High Resolution Melting Analysis Market
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
F. Hoffman-La Roche Ltd.
Bio Farma
QIAGEN
Illumina, Inc.
Agilent Technologies, Inc.
BIOMÉRIEUX
Meridian Bioscience, Inc.
Novacyt
PREMIER Biosoft
Azura Genomics Inc.
Canon Medical Systems Corporation
"The quality of research they have done for us has been excellent..."